Pneuma Respiratory, which is developing a digital soft mist inhaler, announced that it has completed a Series A financing round that raised $8.3 million. The company's Pneumahaler device is a breath activated digital SMI that uses a cartridge system with a microfluidic spray ejector capable of delivering defined droplet sizes. The company said that its … [Read more...] about Pneuma Respiratory raises $8.3 million
News
Pulmatrix announces additional results from Phase 1/1b trial of Pulmazole
Pulmatrix has announced that the 3rd part of its Phase 1/1b study of Pulmazole (PUR1900) itraconazole DPI for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma has been completed and "successfully achieved all objectives." Results from parts 1 and 2 of the study were announced in June 2018. According to the company, 17 patients … [Read more...] about Pulmatrix announces additional results from Phase 1/1b trial of Pulmazole
3M DDS highlights addition of dose indicator on Proventil inhaler
3M Drug Delivery Systems has announced that its Proventil HFA albuterol MDI, which is marketed and distributed by Merck, now includes a top-mounted dose indicator. The FDA approved an sNDA for Proventil HFA with the dose indicator in September 2017, and Merck launched the new version of Proventil HFA in March 2018, according to 3M DDS. 3M Inhalation Drug … [Read more...] about 3M DDS highlights addition of dose indicator on Proventil inhaler
Impel NeuroPharma names Lynn Gold Senior VP of Regulatory Affairs
Intranasal drug developer Impel NeuroPharma has hired Lynn C. Gold as Senior VP of Regulatory Affairs, the company said. Gold was most recently VP of Scientific and Regulatory Affairs at Camargo Pharmaceutical Services and had previously served as VP of Research and Process Development at Sonus Pharmaceuticals. In 2017, Impel announced that it had signed service … [Read more...] about Impel NeuroPharma names Lynn Gold Senior VP of Regulatory Affairs
Hemomont opens nasal spray manufacturing facility in Montenegro
According to reports, Montenegrin pharmaceutical company Hemomont has officially opened a €5.3 million, 1,700 square meter nasal spray manufacturing facility in Podgorica that is expected to employ 30 people and produce 3 million units per month. Montenegrin President Milo Djukanovic attended the opening celebration. Hemomont is a subsidiary of Hemofarm, which is … [Read more...] about Hemomont opens nasal spray manufacturing facility in Montenegro
Gerresheimer gains one inhaler manufacturing order, loses another
In a business update, Gerresheimer announced that it has gained one large order for inhaler manufacturing in Europe but has lost another because "the customer's inhaler business fell short of its expectations." As a result, the company said, it plans to invest in a manufacturing facility in Horsovsky Tyn, the Czech Republic and will close a plant in Küssnacht, … [Read more...] about Gerresheimer gains one inhaler manufacturing order, loses another
Phase 2b study of Oyster Point’s nasal spray for dry eye disease meets primary endpoints
Oyster Point Pharma has announced that the Phase 2b PEARL study of its OC-02 intranasal nicotinic acetylcholine receptor (nAChR) agonist for the treatment of dry eye disease demonstrated a statistically significant increase in production of tear film as well as a statistically significant reduction in symptoms for patients using OC-02 compared to placebo. The … [Read more...] about Phase 2b study of Oyster Point’s nasal spray for dry eye disease meets primary endpoints
Ziccum gets Horizon 2020 grant for dry powder technology
Inhalation Sciences subsidiary Ziccum has been awarded a grant of 500,000 SEK (~ €48,600) by the EU's Horizon 2020 research and innovation project for scale up of its LaminarPace spray drying technology, the company said. A small scale version of LaminarPace is currently in use for creation of dry powder formulations of drugs, vaccines, and biologics. According to … [Read more...] about Ziccum gets Horizon 2020 grant for dry powder technology
TFF Pharmaceuticals announces US patent for DPI particle technology
TFF Pharmaceuticals said that it has received a notice of allowance for US Patent Application No. 12/778,795, titled, "Compositions and Methods of Making Brittle-Matrix Particles Through Blister Pack Freezing," which covers technology related to the company's DPI products for respiratory conditions. Earlier this year, TFF announced that it had raised $14 million … [Read more...] about TFF Pharmaceuticals announces US patent for DPI particle technology
Seqirus gets rights to market Ryaltris nasal spray in Australia and New Zealand
Glenmark Pharmaceuticals has announced that it will receive an unspecified amount up front, plus regulatory and commercial milestone payments, from Seqirus for the rights to commercialize Ryaltris olopatadine hydrochloride/mometasone furoate nasal spray in Australia and New Zealand. In December 2017, Glenmark announced positive results from a Phase 3 trial of … [Read more...] about Seqirus gets rights to market Ryaltris nasal spray in Australia and New Zealand